SCHEMBL4612979

SCHEMBL4612979

COc1ccc([C@@H]2CN(c3cccnn3)C[C@H]2C(=O)N2CC[C@](OC)(c3ccccc3)[C@@H](OC)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MC4R P32245 8/20 0.44
MC3R P41968 5/20 0.44
MC1R Q01726 2/20 0.40
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 3/20 0.36
KDM4E B2RXH2 3/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35
GLS O94925 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
USP7 Q93009 2/20 0.35
CYP3A4 P08684 1/20 0.35
MC5R P33032 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602361 0.92 MC4R (0.44) MC4RMC3RMC1RALDH1A1MEN1
SCHEMBL4940333 0.87 ALDH1A1 (0.37) MC4RALDH1A1MEN1KMT2AHSD17B10
SCHEMBL4601984 0.85 ALDH1A1 (0.37) MC4RALDH1A1MEN1KMT2AHSD17B10
SCHEMBL4612691 0.83 TACR3 (0.38) ALDH1A1MEN1KMT2A
SCHEMBL4936591 0.83 MC4R (0.66) MC4RMC3RMC1RMC5RKCNH2
SCHEMBL4936875 0.79 MC4R (0.65) MC4RMC3RMC1RMC5RKCNH2
SCHEMBL4602241 0.79 MC4R (0.65) MC4RMC3RMC1RMC5RKCNH2
SCHEMBL4941751 0.78 MC4R (0.58) MC4RMC3RMC1RMC5RKCNH2
SCHEMBL4601335 0.74 MC4R (0.52) MC4RMC3RMC1RMC5RKCNH2
SCHEMBL4612769 0.73 MC4R (0.69) MC4RMC3RMC1RMC5RKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024108198-A2 METHODS OF TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-05-23 WO disclosed
US-20080269233-A1 Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds ANDREWS MARK DAVID 2008-10-30 US disclosed
EP-1912968-A1 PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS Pfizer Limited (GB) 2008-04-23 EP disclosed
WO-2007015162-A1 PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS PFIZER LIMITED (GB) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269233-A1 Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds GPR4, GPR119, PRLHR MC4R 4/4885MC3R 86/4885MC1R 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.